• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Deepcell & NVIDIA Partner to Develop Generative AI Models for Single Cell Morphology

by Syed Hamza Sohail 01/10/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

  • Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced a research collaboration with NVIDIA to accelerate the development and adoption of advanced computer vision solutions in life sciences.
  • Deepcell will incorporate NVIDIA AI into its single cell analysis technology, working collaboratively with NVIDIA to codevelop new uses for generative AI and multimodal applications in cell biology. The joint collaboration aims to advance understanding of cell morphology, and ultimately accelerate the use of AI-powered cellular analysis in cell biology and translational research across a broad swath of applications including cancer, stem cell, and cell therapy.

 Revolutionizing Life Sciences Through Cutting-Edge AI Collaboration

Deepcell, in partnership with NVIDIA, is poised to revolutionize life sciences by harnessing the power of multimodal generative AI. This collaboration aims to develop innovative algorithms, utilizing NVIDIA’s Clara suite and computing expertise, to enhance cell image analysis. Deepcell’s REM-I platform, set to be fully commercialized in 2024, integrates high-dimensional cell morphology analysis and sorting capabilities, enabling groundbreaking discoveries in cancer biology, developmental biology, stem cell biology, gene therapy, and more. The synergy between Deepcell’s technological strengths and NVIDIA’s resources promises to usher in a new era of insights and advancements in the field.

“Deepcell has catalyzed the field of morpholomics and showcased the benefits of a

revolutionary new method for single-cell analysis using brightfield cell imaging and artificial

intelligence,” said Mahyar Salek, Ph.D., Cofounder, President, and Chief Technology Officer at

Deepcell. “As we look to the future, we see many possibilities for incorporating multimodal and

generative AI into our platform, and leveraging our proprietary database of billions of cell

images to train additional AI models. Our relationship with NVIDIA will help us accelerate such

enhancements, and bring these advancements to our customers, enabling new discoveries at

unprecedented speed.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |